ArticleJournal of cachexia, sarcopenia and muscle2024
GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients.
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07208916 (Evaluation of Grape Consumption to Improve Muscle Strength and Cognitive Function), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Grape Consumption to Improve Muscle Strength and Cognitive Function
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Pooled it
- Challenges in Identifying Biomarkers of Frailty Syndrome: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Association of plasma growth differentiation factor 15 with wake after sleep onset in mild cognitive impairment.The journal of nutrition, health & aging · 2026Article
- CCL2 and CXCL2 are markers of delirium vulnerability in community dwelling older people.Age and ageing · 2026Article
- Association of plasma growth differentiation factor-15 with the frailty phenotype - Evidence from the COGFRAIL study.The Journal of frailty & aging · 2026Article
- Association between GDF-15 and sarcopenia progression in older adults: results from a population-based study.EBioMedicine · 2026Article
- Association between atrial fibrillation and systemic inflammation with muscle mass and strength trajectories in old age.GeroScience · 2026Article
- Baseline Plasma Growth-differentiation Factor 15 and Recovery of Physical Function Following Total Knee Replacement in the Study of Physical Resilience and Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Biomarkers of Sarcopenia: Current Status and Future Perspectives.Aging medicine (Milton (N.S.W)) · 2026Review
- GFRAL is required to mediate changes in systemic metabolism in response to mitochondrial stress in brown adipose tissue.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Growth differentiation factor 15 predicts physical function impairment in Spanish older adults: a real-world prospective study.GeroScience · 2026Article
- GDF-15 plasma levels are elevated in mobility-limited older adults with frailty and sarcopenia-results from the BIOFRAIL study.GeroScience · 2026Article
- Frailty Exacerbates Disability in Progressive Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Association of inflammatory biomarkers with physical and cognitive frailty in a Spanish population of older adults.GeroScience · 2026Article
- Article
- Associations Between Gut Microbiota and Mitochondrial Metabolites, with Growth Differentiation Factor-15 as a Marker of Oxidative Stress in Heart Failure vs. Healthy Ageing.Antioxidants (Basel, Switzerland) · 2026Article
- Associations Between Growth Differentiating Factor-15 and Frailty in Older Adults From the MAPT Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.Journal of gastroenterology · 2026Review
- Inflammatory biomarkers and sarcopenia in older adults.Frontiers in aging · 2026Article
- The Biological Mechanisms of Frailty: Focusing on Cellular Senescence.European cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGrowth differentiation factor-15 (GDF-15) has been associated with senescence, lower muscle strength, and physical performance in healthy older people. Still, it is not clear whether GDF-15 can be utilized as a biomarker of sarcopenia and frailty in the early stages of hospitalization. We investigated the association of plasma GDF-15 with sarcopenia and frailty in older, acutely admitted medical patients.
methodsThe present study is based on secondary analyses of cross-sectional data from the Copenhagen PROTECT study, a prospective cohort study including 1071 patients ≥65 years of age admitted to the acute medical ward at Copenhagen University Hospital, Bispebjerg, Denmark. Muscle strength was assessed using handgrip strength, and lean mass was assessed using direct segmental multifrequency bioelectrical impedance analyses and used to clarify the potential presence of sarcopenia defined according to guidelines from the European Working Group on Sarcopenia in Older People. Frailty was evaluated using the Clinical Frailty Scale. Plasma GDF-15 was measured using electrochemiluminescence assays from Meso Scale Discovery (MSD, Rockville, MD, USA).
resultsWe included 1036 patients with completed blood samples (mean age 78.9 ± 7.8 years, 53% female). The median concentration of GDF-15 was 2669.3 pg/mL. Systemic GDF-15 was significantly higher in patients with either sarcopenia (P < 0.01) or frailty (P < 0.001) compared with patients without the conditions. Optimum cut-off points of GDF-15 relating to sarcopenia and frailty were 1541 and 2166 pg/mL, respectively.
conclusionsSystemic GDF-15 was higher in acutely admitted older medical patients with sarcopenia and frailty compared with patients without. The present study defined the optimum cut-off for GDF-15, related to the presence of sarcopenia and frailty, respectively. When elevated above the derived cutoffs, GDF-15 was strongly associated with frailty and sarcopenia in both crude and fully adjusted models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.